Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1.

Charles L Loprinzi, Rui Qin, Ernie P Balcueva, Ernie P Baclueva, Kathleen A Flynn, Kendrith M Rowland, David L Graham, Nancy K Erwin, Shaker R Dakhil, Donald J Jurgens, Kelli N Burger

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2010）

Cited 117|Views13
No score
Abstract
Pregabalin decreases hot flashes and is reasonably well tolerated. A target dose of 75 mg twice daily is recommended. Its effects appear to be roughly comparable to what has been reported with gabapentin and with some newer antidepressants.
More
Translated text
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined